Cagnazzo F, et al. - Through a systematic search of 3 databases conducted for studies published from 1990 to 2019, the researchers intended to assess the efficiency of antiplatelet therapy on delayed cerebral ischemia and clinical results in subjects with subarachnoid hemorrhage (SAH). Within 7 studies, 1,060 and 1,762 subjects with SAH were endovascularly or surgically treated with (cases) and without (controls) antiplatelet therapy, respectively. Overall, antiplatelet therapy could not significantly reduce delayed cerebral ischemia rates as compared to the control group. A trend toward lower delayed cerebral ischemia rates following antiplatelet therapy was observed in patients who were treated endovascularly. Long-term (>2 weeks) antiplatelet therapy had a correlation with a lower incidence of delayed cerebral ischemia. Among the antiplatelet therapy group, the good-outcome rate was markedly greater and the mortality rate was markedly lower. Hence, among the antiplatelet therapy group, the prevalence of delayed cerebral ischemia appeared not to be markedly decreased. Nonetheless, among subjects with both long-term antiplatelet therapy and endovascular treatment and antiplatelet administration, delayed cerebral ischemia was observed to be lower. Moreover, among the antiplatelet therapy group, poor results and mortality rates were markedly reduced.